From today, myeloma patients in Scotland will be able to access new myeloma treatment, carfilzomib (Kyprolis®) on the NHS, after […]
An experienced and accomplished healthcare leader has been appointed Chief Executive of Myeloma UK. Rosemarie Finley is joining Myeloma UK […]
The National Institute for Health and Care Excellence (NICE) has approved carfilzomib (Kyprolis®) in combination with dexamethasone for use on […]
Alcentra CEO and philanthropist David Forbes-Nixon has donated £1 million over 5 years to Myeloma UK through the DFN Charitable […]
Researchers have published an article outlining that the Cancer Drugs Fund (CDF), a Government policy designed to provide access to […]
The National Institute for Health and Care Excellence (NICE) has issued a draft “no” on ixazomib (Ninlaro®) for the treatment of patients with relapsed or refractory […]
The National Institute for Health and Care Excellence (NICE) has today published draft negative guidance on daratumumab (Darzalex®) monotherapy used […]
Cancer charity Myeloma UK, has launched MUK eleven, a first of its kind immunotherapy trial which aims to modulate the immune system to target myeloma. The Phase 1b trial will study oncolytic virus, Reolysin® (pelareorep), in combination with immunomodulatory drugs (IMiDs) as a rescue treatment in relapsing myeloma patients.
Myeloma UK has expressed disappointment at news that proposals to introduce a £20m budget impact test for new medicines approved […]
Myeloma UK Policy and Public Affairs Manager Kate Morgan commented, “Myeloma UK made a strong case to the Scottish Medicines Consortium for the approval of both indications and we are very disappointed by the decision not to recommend them for use.